reSET-O app for opioid use disorderFebruary 5, 2019
The US FDA has cleared reSET-O to treat opioid use disorder, Sandoz Inc and Pear Therapeutics, Inc announced.
reSET-O is intended to increase retention of patients with opioid use disorder (OUD) in outpatient treatment. It provides cognitive behavioural therapy (CBT), as an adjunct to outpatient treatment that includes transmucosal buprenorphine medication-assisted-treatment (MAT).
reSET-O is a 12-week interval prescription digital therapeutic (PDT) for OUD. reSET-O is modelled on the community reinforcement approach (CRA) and engineered to deliver CBT for patients with OUD. reSET-O delivers CRA therapy as a series of interactive therapy lessons. Each therapy lesson is comprised of a cognitive behavioural therapy component and skill-building exercises. Therapy lesson content is delivered primarily via text or audio, and may include videos, animations, and graphics.
reSET-O is intended as an adjunct to standard of care for patients with OUD. It is limited to persons with a valid prescription from their licensed provider. reSET-O supports clinician-patient communication between visits, by providing a means for patients to self-report cravings and triggers, and buprenorphine use/non-use. reSET-O reinforces the importance buprenorphine use.